ADAKVEO® (CRIZANLIZUMAB-TMCA)

Policy Number: CS2020D0085A

Effective Date: March 1, 2020

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPLICATION</td>
<td>1</td>
</tr>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>2</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>4</td>
</tr>
<tr>
<td>CENTERS FOR MEDICARE AND MEDICAID SERVICES</td>
<td>4</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>4</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
<td>5</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>5</td>
</tr>
</tbody>
</table>

APPLICATION

This policy does not apply to the states of Florida, Kansas, and Louisiana.

COVERAGE RATIONALE

Adakveo (crizanlizumab-tmca) has been added to the Review at Launch program. Please reference the Medical Benefit Drug Policy titled Review at Launch for New to Market Medications for additional details.

Adakveo is proven and/or medically necessary to reduce the frequency of vasoocclusive crises in patients with sickle cell disease who meet ALL of the following criteria:1-3

Initial Therapy

- Patient is 16 years of age or older; and
- Diagnosis of a sickle cell disease, including, but not limited to, homozygous hemoglobin S [HbSS], sickle hemoglobin C disease [HbSC], sickle beta0 thalassemia, and sickle beta+ thalassemia; and
- Patient has previously experienced 2 or more sickle cell-related vasoocclusive crises within the previous 12 months; and
- One of the following:
  - Patient is currently receiving hydroxyurea therapy
  - Patient has a history of treatment failure, intolerance, or contraindication to hydroxyurea therapy; and
- Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy; and
- Patient is not receiving concomitant Oxbryta (voxelotor) therapy; and
- Adakveo is prescribed by, or in consultation with, a hematologist, or other specialist with expertise in the diagnosis and management of sickle cell disease; and
- Adakveo initial dosing is in accordance with the United States Food and Drug Administration approved labeling: 5 mg/kg by intravenous infusion on week 0, week 2, and every 4 weeks thereafter; and
- Initial authorization will be for no more than 6 months

Continuation Therapy

- Diagnosis of a sickle cell disease, including, but not limited to, homozygous hemoglobin S [HbSS], sickle hemoglobin C disease [HbSC], sickle beta0 thalassemia, and sickle beta+ thalassemia; and
- Patient has experienced a reduction in sickle cell-related vasoocclusive crises and/or a decrease in severity of sickle cell-related vasoocclusive crises from pretreatment baseline while on Adakveo; and
- Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy; and
- Patient is not receiving concomitant Oxbryta (voxelotor) therapy; and
• Adakveo is prescribed by, or in consultation with, a hematologist, or other specialist with expertise in the
diagnosis and management of sickle cell disease; and
• Adakveo maintenance dosing is in accordance with the United States Food and Drug Administration approved
labeling: 5 mg/kg by intravenous infusion every 4 weeks; and
• Reauthorization will be for no more than 12 months

Adakveo is not proven or medically necessary for the treatment of:
• Pediatric patients less than 16 years of age with sickle cell disease
• Myelofibrosis

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all
inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-
covered health service. Benefit coverage for health services is determined by federal, state or contractual
requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not
imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines
may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9399</td>
<td>Unclassified drugs or biologicals</td>
</tr>
<tr>
<td>J3490</td>
<td>Unclassified drugs</td>
</tr>
<tr>
<td>J3590</td>
<td>Unclassified biologics</td>
</tr>
</tbody>
</table>

BACKGROUND

Sickle cell disease (SCD) is the most common monogenic disorder that afflicts approximately 100,000 Americans and
millions of people worldwide. SCD is an inherited group of disorders characterized by the presence of hemoglobin S
(HbS), either from homozygosity for the sickle mutation in the beta globin chain of hemoglobin (HbSS) or from
compound heterozygosity of a sickle beta globin mutation with another beta globin mutation (e.g., sickle-beta
thalassemia). HbS polymerizes when deoxygenated, resulting in red blood cell sickling and membrane damage. These
abnormalities lead to hemolysis, chronic anemia, inflammation, vaso-occlusion, pain crises, end-organ injury, and
premature death. Sickle cell–related pain crises are the primary cause of health care encounters in patients with sickle
cell disease.

CLINICAL EVIDENCE

Crizanlizumab

The efficacy of crizanlizumab was evaluated in patients with sickle cell disease in SUSTAIN (NCT01895361), a 52-
week, randomized, multicenter, placebo-controlled, double-blind trial. A total of 198 patients with sickle cell disease,
any genotype (HbSS, HbSC, HbS/beta0-thalassemia, HbS/beta+–thalassemia, and others), and a history of 2–10
vasoocclusive crises (VOCs) in the previous 12 months were eligible for inclusion. Patients were randomized (1:1:1) to
crizanlizumab 5 mg/kg (N = 67), - 2.5 mg/kg (N = 66), or placebo (N = 65) administered intravenously over 30
minutes on week 0, 2, and every 4 weeks thereafter. Randomization was stratified by prior hydroxyurea (Y/N) and by
the number of VOCs in the prior 12 months and by the number of VOCs in the previous 12 months (2 to 4, 5 to 10).
Seventy percent of patients receiving high-dose crizanlizumab had the HbSS genotype, and 63% of patients were on
concomitant hydroxyurea. Additionally, 63% of patients had 2 to 4 VOCs in the previous 12 months.

The primary efficacy outcome measure was the annual rate of VOCs leading to a healthcare visit, defined as an acute
episode of pain with no cause other than a vaso-occlusive event requiring a medical facility visit and oral or parenteral
opioids, or parenteral NSAIDs. Acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism
(requiring a visit to a medical facility) were also considered VOCs. Secondary efficacy assessments included the
annual rate of days hospitalized, the times to first and second crises, the annual rate of uncomplicated crises (defined
as crises other than the acute chest syndrome, hepatic sequestration, splenic sequestration, or priapism), the annual
rate of the acute chest syndrome, and the Brief Pain Inventory questionnaire.

Patients receiving crizanlizumab, 5 mg/kg, had a lower median annual rate of VOC compared to those receiving
placebo (1.63 vs. 2.98, p=0.01) indicating a 45.3% lower rate with high-dose crizanlizumab. Thirty-six percent of
patients treated with crizanlizumab 5 mg/kg did not experience a VOC compared to 17% in the placebo arm. The
median time to first VOC from randomization was 4.1 vs. 1.4 months in the crizanlizumab 5mg/kg and placebo arm,
respectively.
Reductions in the frequency of VOCs were observed among patients regardless of sickle cell disease genotype, history of crisis frequency and/or hydroxyurea use. The median crisis rate per year among patients receiving concomitant hydroxyurea therapy was 32.1% lower in the high-dose crizanlizumab group compared to the placebo group. The median crisis rate per year among patients who were not receiving concomitant hydroxyurea therapy was 50% lower in the high-dose crizanlizumab group compared to the placebo group. The median crisis rate per year among patients who had had 2 to 4 crises in the previous 12 months was 43% lower in the high-dose crizanlizumab group compared to the placebo group. The median crisis rate per year among patients with the HbSS genotype was 34.6% lower in the high-dose crizanlizumab group compared to the placebo group. The median crisis rate per year among patients without the HbSS genotype was 50.5% lower in the high-dose crizanlizumab group compared to the placebo group.

Among the secondary endpoints, the median time to the first crisis was significantly longer among patients receiving high-dose crizanlizumab than among those receiving placebo (4.07 vs. 1.38 months, P = 0.001), as was the median time to the second crisis (10.32 vs. 5.09 months, P = 0.02). The lower crisis frequency with high-dose crizanlizumab was evident within 2 weeks after the start of the 52-week treatment phase and was maintained throughout the study. The rate of uncomplicated crises per year was 62.9% lower in the high-dose crizanlizumab group than in the placebo group (median rate, 1.08 vs. 2.91; P = 0.02). There was no significant difference in the median rates of days hospitalized or in change from baseline of the Brief Pain Inventory questionnaire with high-dose crizanlizumab. Additionally in the clinical trial, acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism were rare (median rate, 0.00 in all groups), and there were no significant differences between the treatment group and placebo.

No significant differences were observed with crizanlizumab compared to placebo in markers of hemolysis, such as hemoglobin, lactate dehydrogenase, haptoglobin, reticulocytes, and indirect bilirubin.

Hydroxyurea

The Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH) was a randomized, double blind, placebo-controlled trial involving 299 adults with SCA who had experienced three or more VOCs in the previous year. The clinical end point of three or more documented VOCs was chosen because of earlier data documenting that people who experience pain at that frequency had markedly lower survival rates. The MSH trial demonstrated that, compared to placebo, hydroxyurea therapy reduced the frequency of painful episodes and ACS events, as well as the need for RBC transfusions and hospitalizations. In 1998, based on the results of this trial, the U.S. Food and Drug Administration approved hydroxyurea for the treatment of clinically severe SCA in adults.

Summary of MSH Findings:
- Lower annual rates of pain crises (median 2.5 crises per year vs. 4.5 crises per year)
- Longer time to a first crisis on study (3.0 months vs. 1.5 months) and longer time to a second crisis (8.8 months vs. 4.6 months)
- Lower incidence of ACS (25 patients vs. 51 patients)
- Reduced need for blood transfusions (48 patients vs. 73 patients)
- Increased total hemoglobin (0.6 g/dL) and HbF (from 5.0 to 8.6 percent in the intervention group), compared with a drop in the placebo group (from 5.2 to 4.7 percent)
- Lower costs for hospitalization for pain ($12,160 in the hydroxyurea group versus $17,290 in the placebo group)
- Differences in the effect on mortality and stroke outcomes were not statistically significant.

National Heart, Lung and Blood Institute (NHLBI) 2014 Evidence Report Recommendations for Hydroxyurea Therapy in the Management of Sickle Cell Disease

- Educate all patients with SCA and their family members about hydroxyurea therapy (Consensus–Panel Expertise)
- In adults with SCA who have three or more sickle cell-associated moderate to severe pain crises in a 12-month period, treat with hydroxyurea (Strong Recommendation, High-Quality Evidence)
- In adults with SCA who have sickle cell-associated pain that interferes with daily activities and quality of life, treat with hydroxyurea (Strong Recommendation, Moderate-Quality Evidence)
- In adults with SCA who have a history of severe and/or recurrent ACS, treat with hydroxyurea* (Strong Recommendation, Moderate-Quality Evidence)
- In adults with SCA who have severe symptomatic chronic anemia that interferes with daily activities or quality of life, treat with hydroxyurea (Strong Recommendation, Moderate-Quality Evidence)
- In infants 9 months of age and older, children, and adolescents with SCA, offer treatment with hydroxyurea regardless of clinical severity to reduce SCD-related complications (e.g., pain, dactylitis, ACS, anemia) (Strong Recommendation, High-Quality Evidence for ages 9–42 months; Moderate Recommendation, Moderate-Quality Evidence for children >42 months and adolescents)
• In adults and children with SCD who have chronic kidney disease and are taking erythropoietin, hydroxyurea therapy can be added to improve anemia (Weak Recommendation, Low-Quality Evidence)
• In females who are pregnant or breastfeeding, discontinue hydroxyurea therapy (Moderate Recommendation, Very Low-Quality Evidence)
• To ensure proper use of hydroxyurea and maximize benefits and safety, use an established prescribing and monitoring protocol (Strong Recommendation, High-Quality Evidence)
• In people with HbS beta-thalassemia or HbSbeta-thalassemia who have recurrent sickle cell-associated pain that interferes with daily activities or quality of life, consult a sickle cell expert for consideration of hydroxyurea therapy (Moderate Recommendation, Low-Quality Evidence)
• In people not demonstrating a clinical response to appropriate doses and duration of hydroxyurea therapy, consult a sickle cell expert (Moderate Recommendation, Very Low-Quality Evidence)

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Adakveo® (crizanlizumab-tmca) is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

The safety and efficacy of Adakveo in pediatric patients below the age of 16 years have not been established.

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

Medicare does not have a National Coverage Determination (NCD) for Adakveo® (crizanlizumab-tmca). Local Coverage Determinations (LCDs) do not exist at this time.

In general, Medicare may cover outpatient (Part B) drugs that are furnished "incident to" a physician's service provided that the drugs are not usually self-administered by the patients who take them. Refer to the Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals. (Accessed November 21, 2019)

REFERENCES

POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/01/2020</td>
<td>• New Medical Benefit Drug Policy</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.